AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2021

Jun 15, 2021

32254_dirs_2021-06-15_b49d6b88-dd85-4f69-836e-31cf3f9a26f2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2021-06-14

Reporting Person: Paggiarino Dario A. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-14	Common Stock	M	1420.00	$0.00	Acquired	13012.00	Direct
2021-06-14	Common Stock	F	417.00	$9.72	Disposed	12595.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-14	Restricted Stock Units	$0.00	M	1420.00	Disposed		Common Stock (1420.00)	Direct

Footnotes

F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

F2: Vests in three annual installments beginning on 14-Jun-2019